A drawback of this paper is that even though we identified SNAP25 as a potential and available drug invention target for AD and PD, further validation of the effectiveness and sensitivity of SNAP25 as a potential target in the OE is still lacking. The gene discussed is SNAP25; the disease is Parkinson disease.